STATE OF NEVADA



DR. KRISTOPHER SANCHEZ

Director

PERRY FAIGIN NIKKI HAAG MARCEL F. SCHAERER Deputy Directors

A.L. HIGGINBOTHAM Executive Director

DEPARTMENT OF BUSINESS AND INDUSTRY OFFICE OF NEVADA BOARDS, COMMISSIONS AND COUNCILS STANDARDS NEVADA STATE BOARD OF DENTAL EXAMINERS

Draft Advisory Opinion

Subject: Appropriate Medications and Dosage Ranges for Permit Holders Performing Moderate Sedation

(Prepared for Board consideration at the May 14, 2025 meeting based on discussions held at the Anesthesia Committee and Sub-Committee Meeting on April 30, 2025.)

1. Purpose

To communicate the Board's expectations regarding the selection and dosage of sedative-analgesic medications used by Nevada permit holders who are authorized to provide moderate (conscious) sedation, and to clarify how the Board will evaluate permit applications and clinical records that appear to deviate from those expectations.

The subject was discussed on April 30, 2025, at the Anesthesia Committee and Sub-Committee Meeting. Committee members present included Chairperson Dr. Joshua Branco, Board President Dr. Ronald West, Board Member Dr. Christopher Hock, Board Member Dr. Ashley Hoban, and Board Member Dr. Joan Landron. Sub-Committee members present included Dr. Amanda Okundaye, Dr. Kevin Moore, Dr. James Schlesinger, and Dr. Ted Twesme.

2. Statutory & Regulatory Authority

- NRS 631.190 Powers and duties of the Board to protect the public health and safety in licensing decisions.
- NAC 631.030 Establishes coursework, case-experience, and record-submission requirements.
- NAC 631.2211 NAC 631.2256 Establishes the administration of general anesthesia, moderate sedation or deep sedation.
- NAC 631.2212 Authorizes the Board, when determining the true level of sedation achieved or proposed, to rely on "the type and dosage of medication that was administered or is proposed for administration."

3. Committee Determination

1. Package-Insert Benchmark

The dosage and titration ranges outlined in FDA package inserts serve as the Board's baseline guidance for medications used under a moderate-sedation permit.

2. Case-by-Case Review

 Records showing cumulative doses that materially exceed package-insert maximums, or that in the Board's clinical judgment would reasonably produce deep or general anesthesia, will trigger enhanced review and may result in permit denial, or other Board action.

3. Training-Program Oversight

• When multiple graduates of a single course display outlier dosing patterns, the Board may require the program to supply additional randomly selected graduate records and may reopen the program's approval status with the Board.

4. Effective Date

This Advisory Opinion becomes effective upon formal adoption by the Board and applies to all pending and future moderate sedation permit matters.

5. Reservation of Authority

Nothing in this opinion limits the Board's discretion to impose stricter conditions, require remedial education, or pursue disciplinary measures when patient safety so requires.

Prepared by Board staff pursuant to the motion approved by the Anesthesia Committee on April 30, 2025.